These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20978273)

  • 1. Reading performance as a function of treatment with lisdexamfetamine dimesylate in elementary school children diagnosed with ADHD.
    Wigal SB; Maltas S; Crinella F; Stehli A; Steinhoff K; Lakes K; Schuck S
    J Atten Disord; 2012 Jan; 16(1):23-33. PubMed ID: 20978273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
    BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.
    Waxmonsky JG; Waschbusch DA; Babinski DE; Humphrey HH; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    CNS Drugs; 2014 Jul; 28(7):665-77. PubMed ID: 24796970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
    J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
    Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
    Turgay A; Ginsberg L; Sarkis E; Jain R; Adeyi B; Gao J; Dirks B; Babcock T; Scheckner B; Richards C; Lasser R; Findling RL
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):503-11. PubMed ID: 21186969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Childress AC; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Findling RL
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):210-7. PubMed ID: 24815910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
    Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase synchronization of oxygenation waves in the frontal areas of children with attention-deficit hyperactivity disorder detected by optical diffusion spectroscopy correlates with medication.
    Wigal SB; Polzonetti CM; Stehli A; Gratton E
    J Biomed Opt; 2012 Dec; 17(12):127002. PubMed ID: 23232795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments.
    Katic A; Dirks B; Babcock T; Scheckner B; Adeyi B; Richards C; Findling RL
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):386-93. PubMed ID: 23952185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.